Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice

Journal of Molecular Medicine

Volumn 94, Issue 8, 2016, Pages 957-966

  Schwengel, Katja ^a   Namsolleck, Pawel ^b   Lucht, Kristin ^a   Clausen, Bettina H ^c   Lambertsen, Kate L ^c   Valero Esquitino, Veronica ^a   Thöne Reineke, Christa ^d   Müller, Susanne ^e   Widdop, Robert E ^f   Denton, Kate M ^f   Horiuchi, Masatsugu ^g   Iwai, Masaru ^g   Boato, Francesco ^h   Dahlöf, Björn ⁱ   Hallberg, Anders ^j   Unger, Thomas ^b   Steckelings, U Muscha ^c  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MONASH UNIVERSITY   (Australia)

^g EHIME UNIVERSITY   (Japan)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

AT2 receptor; MCAO; Neuroprotection; Renin angiotensin system; Stroke

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; MESSENGER RNA; NEUROMODULIN; UNCLASSIFIED DRUG; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; NEUROPROTECTIVE AGENT; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN NERVE CELL; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL STROKE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOUSE; NERVE FIBER GROWTH; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REPERFUSION; SURVIVAL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UPREGULATION; AGONISTS; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY;

ANIMALS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CEREBRAL CORTEX; DRUG EVALUATION, PRECLINICAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; THIOPHENES;

EID: 84962620652     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-016-1406-3     Document Type: Article

References (33)

1. Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM (2013) Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol 40:580–588
2. Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N (1996) Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 271:22729–22735
3. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T (1996) The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 122:59–67
4. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T (1998) The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 188:661–670
5. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T (2003) Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 17:2094–2096
6. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, Thöne-Reineke C, Lucht K, Seidel K, Hallberg A et al (2013) AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis 51:177–191
7. Iwai M, Liu H-W, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M (2004) Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110:843–848
8. Li J, Culman J, Hörtnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U et al (2005) Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19:617–619
9. McCarthy CA, Vinh A, Callaway JK, Widdop RE (2009) Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 40:1482–1489
10. McCarthy CA, Vinh A, Broughton BRS, Sobey CG, Callaway JK, Widdop RE (2012) Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension 60:1531–1537
11. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A et al (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47:5995–6008
12. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlöf B, Unger T (2011) Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 11:187–192
13. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E et al (2009) Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 27:2444–2451
14. Min L-J, Mogi M, Tsukuda K, Jing F, Ohshima K, Nakaoka H, Kan-No H, Wang XL, Chisaka T, Bai HY et al (2014) Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens 27:1036–1044
15. Alhusban A, Fouda AY, Pillai B, Ishrat T, Soliman S, Fagan SC (2015) Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens 33:170–180
16. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, Patel NA, Pioquinto DJ, Unger T, Katovich MJ et al (2014) The angiotensin type 2 receptor agonist compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 81:134–141
17. McCarthy CA, Vinh A, Miller AA, Hallberg A, Alterman M, Callaway JK, Widdop RE (2014) Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One 9:e95762
18. Brunner E (2002) Nonparametric analysis of longitudinal data in factorial experiments. J. Wiley, New York
19. Sendtner M, Holtmann B, Kolbeck R, Thoenen H, Barde YA (1992) Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature 360:757–759
20. Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T (1991) The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65:895–903
21. Denny JB (2006) Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43. Curr Neuropharmacol 4:293–304
22. Skene JH, Willard M (1981) Axonally transported proteins associated with axon growth in rabbit central and peripheral nervous systems. J Cell Biol 89:96–103
23. Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10:209–219
24. Schäbitz WR, Schwab S, Spranger M, Hacke W (1997) Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:500–506
25. Yamashita K, Wiessner C, Lindholm D, Thoenen H, Hossmann KA (1997) Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab Brain Dis 12:271–280
26. Pardridge WM, Kang YS, Buciak JL (1994) Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res 11:738–746
27. Biffo S, Offenhäuser N, Carter BD, Barde YA (1995) Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development. Development 121:2461–2470
28. Williams LR (1991) Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp Neurol 113:31–37
29. Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ (1997) Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol 41:82–93
30. Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, Shelton DB, McMahon SB, Thompson SW (1999) Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 19:5138–5148
31. Groth R, Aanonsen L (2002) Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia. Pain 100:171–181
32. Benowitz LI, Routtenberg A (1997) GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20:84–91
33. Fournier AE, Beer J, Arregui CO, Essagian C, Aguayo AJ, McKerracher L (1997) Brain-derived neurotrophic factor modulates GAP-43 but not T alpha1 expression in injured retinal ganglion cells of adult rats. J Neurosci Res 47:561–572